ObsEva Annual General Meeting 2021
ObsEva SA (NASDAQ: OBSV) has announced its 2021 Annual General Meeting of Shareholders to be held on May 28, 2021, in Geneva. The agenda includes the approval of financial statements for fiscal year 2020, where the company reported a net loss of USD 75,216,317, increasing total accumulated losses to USD 328,451,570. The board recommends discharging the executive committee from liability for their actions in 2020. Additionally, several board members are up for re-election, including Franciscus Verwiel as Chairman.
- Re-election proposals for board members including experienced candidates like Franciscus Verwiel.
- Appointment of Catarina Edfjäll and Brian O’Callaghan, who bring extensive industry expertise.
- Reported net loss of USD 75,216,317 for 2020, contributing to total losses of USD 328,451,570.
Geneva, Switzerland and Boston, MA – April 22, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published the invitation to its 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 at 16:30 CEST at the company’s offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
The agenda of the meeting will be as follows:
1 Approval of the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2020
The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2020 be approved.
2 Discharge of Liability for the Members of the Board of Directors and of the Executive Committee.
The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2020.
3 Appropriation of Financial Results.
The Board of Directors proposes that the loss of USD 75,216,317 for the financial year 2020 be appropriated as follows:
| Financial Year 2020 | |
| Accumulated losses brought forward from previous year | USD 253,235,253 |
| Net loss for the year 2020 | USD 75,216,317 |
| Accumulated losses to be carried forward | USD 328,451,570 |
4 Elections to the Board of Directors and Election of the Chairman of the Board of Directors
The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:
4.1 Re-election of Franciscus Verwiel as member and Chairman of the Board of Directors
4.2 Re-election of Annette Clancy as member of the Board of Directors
4.3 Re-election of Barbara Duncan as member of the Board of Directors
4.4 Re-election of Ernest Loumaye as member of the Board of Directors
4.5 Re-election of Edward Mathers as member of the Board of Directors
4.6 Re-election of Jacky Vonderscher as member of the Board of Directors
Jim Irvin Healy and Rafaele Elisabete Tordjman are not standing for re-election.
The Board of Directors further proposes the election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:
4.7 Election of Catarina Edfjäll as member of the Board of Directors
Catarina Edfjäll is a Global Regulatory Affairs Expert with more than 25 years of experience in the biotech and pharma sector, now working as an independent consultant and mentor. She has profound drug development experience across the entire product lifecycle, from development to launch, and across many therapeutic areas, including rare diseases. She was responsible for the successful regulatory approval of 20 innovative medicinal products and new indications in more than 50 countries. In her most recent senior management role, Catarina was the global head of regulatory affairs at CSL Behring. Prior to that, she held leadership positions in regulatory affairs at companies formerly known as Actelion, Celgene and Shire, and, started her career at F. Hoffmann-La Roche.
Catarina is a Board Member at the Cancer Drug Development Forum (CDDF) and at the International Collaboration on Rare Diseases & Orphan Drugs (ICORD), both non-profit organisations. She has been actively involved in several multi-stakeholder organisations, including the European Medicines Agency´s Committee for Orphan Medicinal Products´ Working Group with Interested Parties.
Catarina holds a Master in biotechnology engineering from the Ecole Supérieure de Biotechnologie in Strasburg, a Ph.D. in biochemistry from the University in Basel and a Corporate Governance Certification from the Swiss Board School and the University of St Gallen.
The mandate of Catarina Edfjäll as member of the Board of Directors would only be effective as of June 30, 2021.
4.8 Election of Brian O’Callaghan as member of the Board of Directors
Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and CRO sectors. He also has extensive global experience, having lived and worked in 5 different countries, as well as both sides of the US. He joined ObsEva in November 2020, as Chief Executive Officer to lead the Company through its future development, regulatory filings and product launches.
FAQ
What is the date of ObsEva's Annual General Meeting in 2021?
What was ObsEva's net loss for the fiscal year 2020?
Who is proposed for re-election on ObsEva's Board of Directors?
What are the accumulated losses for ObsEva as of 2020?
Who are the new board members proposed for election at ObsEva?
